Anzeige
Mehr »
Montag, 21.09.2026 - Börsentäglich über 12.000 News
Auf diese Liste kann man sich nicht einkaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
BD

WKN: A12EKB | ISIN: CA09073K1084 | Ticker-Symbol: 20B
Frankfurt
21.09.26 | 20:15
0,288 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOMARK DIAGNOSTICS INC Chart 1 Jahr
5-Tage-Chart
BIOMARK DIAGNOSTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2880,32821:01

Aktuelle News zur BIOMARK DIAGNOSTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:38BioMark Diagnostics, Inc.: BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences253The Company will provide an update on the clinical translation of its biomarker platform and showcase industry collaborations supporting scalable, high-throughput mass spectrometry.Vancouver, British...
► Artikel lesen
25.08.Biomark Diagnostics Inc: Biomark releases lung cancer assay study results1
BIOMARK DIAGNOSTICS Aktie jetzt für 0€ handeln
25.08.BioMark Diagnostics, Inc.: BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy7.829Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy...
► Artikel lesen
31.07.Biomark Diagnostics Inc: Biomark backs lung cancer screening1
31.07.BioMark Diagnostics, Inc.: BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day408Vancouver, British Columbia--(Newsfile Corp. - July 31, 2026) - As the global healthcare community unites on August 1st to observe World Lung Cancer Day, BioMark Diagnostics Inc. (CSE: BUX) (FSE:...
► Artikel lesen
23.06.BioMark Diagnostics, Inc.: BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test386Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies...
► Artikel lesen
10.06.Biomark Diagnostics Inc: Biomark receives U.S. patent1
09.06.BioMark Diagnostics secures USPTO patent approval for urine-based lung cancer test6
09.06.BioMark Diagnostics, Inc.: BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform436Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies...
► Artikel lesen
14.04.BioMark Diagnostics, Inc.: BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum282Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy...
► Artikel lesen
15.01.BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology491Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for...
► Artikel lesen
31.12.25BioMark Diagnostics, Inc.: BioMark: 2025 Achievements & 2026 Vision753Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy...
► Artikel lesen
30.12.25BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors551Vancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy...
► Artikel lesen
23.12.25BioMark Diagnostics, Inc.: BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program484Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer...
► Artikel lesen
01.12.25BioMark Diagnostics, Inc.: BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala470Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early...
► Artikel lesen
12.11.25BioMark Diagnostics, Inc.: BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy559Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading...
► Artikel lesen
07.10.25BioMark Diagnostics, Inc.: BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial605Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early...
► Artikel lesen
29.09.25BioMark Diagnostics, Inc.: BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy517Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1